Description

BSE notifies transfer of Goldline Pharmaceutical Limited SME IPO equity shares from Trade for Trade segment (MT Group) to Rolling segment (M Group) effective June 3, 2026.

Summary

BSE has announced that the equity shares of Goldline Pharmaceutical Limited (SME IPO, Scrip Code: 544759) will be transferred from the Trade for Trade segment (MT Group) to the Rolling segment (M Group) with effect from Wednesday, June 3, 2026. This notice is a continuation of Exchange Notice No. 20260518-28 dated May 18, 2026.

Key Points

  • Equity shares of Goldline Pharmaceutical Limited (Scrip Code: 544759) will move from Trade for Trade (MT Group) to Rolling segment (M Group).
  • Effective date of the segment transfer is Wednesday, June 3, 2026.
  • This is a continuation of Notice No. 20260518-28 dated May 18, 2026.
  • Department: DCS-Listing; Segment: SME.
  • Contact person for queries: Mr. Anurag Jain, Tel. No. 022-2272 8822.

Regulatory Changes

The trading classification of Goldline Pharmaceutical Limited equity shares is being changed from the Trade for Trade settlement segment (MT Group) to the Rolling settlement segment (M Group). This change alters the settlement mechanism applicable to trades in this scrip.

Compliance Requirements

  • Trading Members must note the change in settlement segment effective June 3, 2026.
  • Members should update their systems and processes to reflect the new M Group classification for Scrip Code 544759.
  • For further clarifications, Trading Members may contact Mr. Anurag Jain at Tel. No. 022-2272 8822.

Important Dates

  • May 18, 2026: Original notice (No. 20260518-28) issued.
  • May 19, 2026: Continuation notice issued.
  • June 3, 2026: Effective date for transfer from MT Group (Trade for Trade) to M Group (Rolling segment).

Impact Assessment

This segment migration is a standard transition for SME IPO stocks after the mandatory Trade for Trade period. Moving to Rolling settlement (M Group) increases liquidity and trading flexibility for investors, as trades will now be settled on a net basis rather than gross trade-for-trade basis. Trading members dealing in this scrip should update their risk and settlement systems accordingly before June 3, 2026. The impact is moderate and limited to participants trading Goldline Pharmaceutical Limited shares.

Impact Justification

Routine segment migration from MT Group (Trade for Trade) to M Group (Rolling) for an SME IPO stock; affects trading mechanics for members dealing in this scrip but is a standard post-IPO transition.